Tandem Diabetes Care achieved record quarterly sales of $290.4 million and a record gross margin of 58% in Q4 2025, demonstrating strong operational improvement and key portfolio enhancements, including the global commercial rollout of t:slim X2 pump integration with FreeStyle Libre 3 Plus and the launch of Android mobile control for the Tandem Mobi system.

Tandem Diabetes Care achieved record second quarter sales of $240.7 million, demonstrating year-over-year and sequential gross margin improvement. The company reported a GAAP net loss of $52.4 million and a non-GAAP net loss of $32.4 million, while increasing U.S. pump shipments and advancing key product and commercial initiatives.

Tandem Diabetes Care achieved record first quarter sales in Q1 2025, driven by strong worldwide growth and significant increases in pump shipments both domestically and internationally. The company also improved its adjusted EBITDA margin.

Tandem Diabetes Care achieved record sales in Q4 2024, with worldwide GAAP sales growing 44% to $282.6 million and worldwide non-GAAP sales growing 21% to $252.4 million. The company also saw a more than 25% increase in worldwide pump shipments and a return to positive free cash flow for the full year.

Tandem Diabetes Care reported a successful third quarter in 2024, achieving the highest quarterly sales in the company's history. Worldwide GAAP sales increased by 31% to $244.0 million compared to Q3 2023. The company also demonstrated positive Adjusted EBITDA and a return to positive free cash flow, leading to an increase in full year 2024 sales guidance.

Tandem Diabetes Care announced its Q2 2024 financial results, reporting a 13% increase in worldwide GAAP sales to $221.9 million. The company also launched Tandem Mobi with Dexcom G7 integration and completed enrollment for a Control-IQ study. Sales guidance for the full year 2024 has been increased.

Tandem Diabetes Care reported a 13% increase in worldwide GAAP sales, reaching $191.7 million, and a 9% increase in worldwide pump shipments to approximately 25,000 pumps. The company launched Tandem Mobi with Dexcom G6 integration and t:slim X2 with Abbott Freestyle Libre 2 Plus integration in the U.S., and initiated the rollout of t:slim X2 with Dexcom G7 integration outside the U.S. They also received FDA clearance to expand the Tandem Mobi pump indication.

Tandem Diabetes Care announced positive momentum across key areas, including the introduction of four new products in the United States. The company's portfolio positions them to improve the lives of more people living with diabetes worldwide, while driving operational improvement across their business.

Tandem Diabetes Care reported a decrease in sales and gross profit compared to the same quarter last year. The company is focused on expanding the adoption of automated insulin delivery and managing costs.

Tandem Diabetes Care reported second quarter 2023 financial results, demonstrating progress with new technology innovations and achieving sales expectations. The company updated its full year 2023 financial guidance, anticipating disruption from market releases and focusing on new offerings and operational efficiencies.

Tandem Diabetes Care announced its Q1 2023 financial results, reporting worldwide sales of $169.38 million and a GAAP net loss of $123.87 million. The company reaffirmed its full year 2023 financial guidance.

Tandem Diabetes Care reported its Q4 2022 financial results, with worldwide sales increasing to $220.5 million. The company's GAAP gross profit increased to $115.5 million, and despite a GAAP operating loss of $17.8 million, Adjusted EBITDA reached $25.7 million.

Tandem Diabetes Care reported a 14% increase in worldwide sales, reaching $204.5 million. The installed base grew by 35% to over 400,000 customers. However, the company is factoring greater caution into its guidance due to a highly variable environment and the timing of potential new product introductions.

Tandem Diabetes Care reported a 16% increase in worldwide sales, reaching $200.3 million, driven by growth in both domestic and international markets. The company launched new features for its t:slim X2 insulin pump and progressed in studies for type 2 diabetes and expanded insulin indications.

Tandem Diabetes Care reported a 25% increase in first-quarter sales to $175.9 million compared to the same period in 2021. Worldwide pump shipments increased by 11% to 28,095 pumps. The company updated its full-year financial guidance, projecting sales between $850 million and $865 million.

Tandem Diabetes Care announced strong Q3 2021 results with a 45% increase in sales to $179.6 million and a significant rise in worldwide pump shipments by 43%. The company also updated its full-year sales guidance to $685 million - $695 million.

Tandem Diabetes Care reported a strong second quarter with a 58% increase in sales to $172.1 million and an 81% increase in worldwide pump shipments. The company updated its full-year sales guidance to $670 million to $685 million.

Tandem Diabetes Care announced a strong start to 2021 with record first-quarter sales, driven by increased pump shipments and international growth. The company updated its full-year sales guidance, reflecting confidence in continued positive momentum.

Tandem Diabetes Care reported a strong fourth quarter with a 55% increase in sales and a 67% increase in worldwide pump shipments. The company's operating margin improved significantly, and they surpassed 200,000 customers worldwide.

Tandem Diabetes Care reported a 31% increase in sales to $123.6 million and an improved operating margin of negative 1 percent in Q3 2020. Worldwide pump shipments increased 23 percent to 22,021 pumps.

Tandem Diabetes Care reported a 17% increase in worldwide sales, reaching $109.2 million for the second quarter of 2020. The company successfully completed its first acquisition and executed multiple agreements. They are reinstating the sales guidance they set at the beginning of 2020.

Tandem Diabetes Care reported a 48% increase in sales to $97.9 million and a gross margin of 51% for the first quarter of 2020. Worldwide pump shipments increased by 18% compared to the same period in 2019. However, due to the COVID-19 pandemic, the company withdrew its full-year financial guidance.

Tandem Diabetes Care reported a 42% increase in sales for the fourth quarter of 2019, reaching $108.4 million, and a net income of $2.7 million. The company's worldwide pump shipments increased by 21% compared to the same period in 2018. They are guiding for sales between $450 million and $465 million for the year ending December 31, 2020.